Pharmaceuticals

Remicade Biosimilar Market Growth Opportunities: Insights from 2025–2029

November 7, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

By How Much Is The Remicade Biosimilar Market Expected To Expand Between 2025 And 2029?

Recent years have witnessed an exponential increase in the remicade biosimilar market size. This market is projected to expand from $3.95 billion in 2024 to $4.89 billion by 2025, demonstrating a compound annual growth rate (CAGR) of 23.8%. Factors contributing to this historic growth include the introduction of remicade (infliximab), alongside biotechnology advancements, the expiry of biologics patents, the establishment of regulatory pathways, and pressures related to healthcare costs.

The remicade biosimilar market size is set for significant expansion in the coming years, with forecasts indicating a rise to $10.89 billion by 2029, driven by a compound annual growth rate (CAGR) of 22.2%. This projected growth throughout the forecast period is influenced by several factors, including patent expirations, an increasing need for cost-effective therapies, progress in biosimilar pipeline development, favorable reimbursement policies, and market consolidation. Noteworthy trends anticipated during this period involve changes in physician prescribing behavior, strategies for biosimilar lifecycle management, the adoption of specific biosimilar naming conventions, considerations of biosimilar interchangeability, and the accumulation of biosimilar real-world evidence.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11952&type=smp

What Are The Emerging Market Drivers Creating New Opportunities In The Remicade Biosimilar Industry?

The remicade biosimilar market is poised for growth, primarily driven by the rising incidence of autoimmune diseases. These are disorders where the immune system mistakenly attacks and damages the body’s own tissues and organs. Remicade biosimilars serve as an effective therapeutic option for treating such conditions, helping to manage symptoms and reduce associated inflammation. Supporting this trend, data from Public Health Scotland, a national organization based in Scotland, indicated in July 2023 that newly diagnosed multiple sclerosis (MS) patients in 2022 increased to 87.2%, up from 85.7% in 2020, with 491 new cases reported, leading to a total of 6,359 cases in 2022. This consistent increase in autoimmune disease cases is therefore a significant factor propelling the expansion of the remicade biosimilar market.

What Are The Major Segment Categories Driving The Remicade Biosimilar Market Growth?

The remicade biosimilar market covered in this report is segmented –

1) By Type: 100mg/10ml, 500mg/50ml

2) By Disease Indication: Ulcerative Colitis, Rheumatoid Arthritis, Ankylosing Spondylitis, Crohn’s Disease, Psoriatic Arthritis, Plaque Psoriasis

3) By Application: Blood Disorders, Oncology Diseases

Subsegments:

1) By 100 Mg/10 Ml: Vials For Injection, Prefilled Syringes

2) By 500 Mg/50 Ml: Vials For Injection, Prefilled Syringes

What Long-Term Trends Will Shape The Future Growth Of The Remicade Biosimilar Industry?

A significant and growing trend within the Remicade biosimilar market is product innovation. Leading firms active in this sector are engaged in creating novel products to maintain their competitive standing. An illustration of this is Amgen Inc., a US-based biotechnology company, introducing Amjevita, a biosimilar iteration of AbbVie’s Humira, in the US in January 2023, engineered to match the safety and efficacy of its reference product. As the initial biosimilar for Humira, Amjevita is projected to contend for market share against it. Humira, a biological medication prescribed for numerous autoimmune conditions like rheumatoid arthritis and Crohn’s disease, stands among the world’s priciest pharmaceuticals, bringing in billions of dollars in annual sales for AbbVie. Amjevita is anticipated to be considerably more affordable and, beyond cost savings, it can also present patients with a broader array of treatment alternatives.

Who Are The Core Companies Influencing The Remicade Biosimilar Market Landscape?

Major companies operating in the remicade biosimilar market include Novartis AG, Amgen Inc, Viatris Inc., Teva Pharmaceutical Industries Ltd., Biogen Inc., Merck And Co. Inc., LG Chem Ltd., Nippon Kayaku Co. Ltd., Celltrion Inc., Nichi-iko Pharmaceutical Co. Ltd., Biocon Limited, Alvotech S.A., MabPharm Ltd., Genor Biopharma Co. Ltd, Shanghai Biomabs Pharmaceuticals Co. Ltd., Samsung Bioepis Co. Ltd., Biocad Biopharmaceutical Co, EPIRUS Biopharmaceuticals Inc., Ranbaxy Laboratories Limited, BioXpress Therapeutics SA, Mabion S.A

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/remicade-biosimilar-global-market-report

Which Region Shows The Highest Potential For Future Expansion In The Remicade Biosimilar Market?

Europe was the largest region in the remicade biosimilar market in 2024. The regions covered in the remicade biosimilar market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Remicade Biosimilar Market Report:

https://www.thebusinessresearchcompany.com/customise?id=11952&type=smp

Browse Through More Reports Similar to the Global Remicade Biosimilar Market 2025, By The Business Research Company

Biostimulants Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/biostimulants-global-market-report

Agroscience Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/agroscience-global-market-report

Agricultural Biologics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/agricultural-biologics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795